Small Cell Lung Cancer

Cancer therapeutics development company files IND for small cell lung cancer

Published in Medical Letter on the CDC and FDA, November 28th, 2004

NeoRx Corporation (NASDAQ:NERX) announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for a phase II clinical trial of NX 473, the company's next generation platinum product candidate, in patients with small cell lung cancer (SCLC).

"Our first IND for NX 473 represents a significant step toward our goal to develop and commercialize a diverse pipeline of oncology products," said Jerry McMahon, PhD, chairman and chief executive officer of NeoRx. "Our plan is to initiate the lung cancer Phase II trial in the first half of 2005, followed by a pilot study with NX 473 for the treatment of colorectal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry